Literature DB >> 15671302

Effect of benzalkonium chloride on transscleral drug delivery.

Komei Okabe1, Hideya Kimura, Junko Okabe, Aki Kato, Hideo Shimizu, Takashi Ueda, Shouichi Shimada, Yuichiro Ogura.   

Abstract

PURPOSE: To investigate the effect and safety of benzalkonium chloride on transscleral drug delivery in the rabbit after continuous intrascleral administration.
METHODS: Betamethasone 21-phosphate (BP) aqueous solutions, with or without benzalkonium chloride (BAK), were continuously administered to albino rabbit sclera with an osmotic pump for 1 week. The BP concentrations in the aqueous humor, vitreous, and retina-choroid were measured by high-performance liquid chromatography (HPLC). To investigate the effect of BAK on scleral permeability of BP in vitro, penetration of BP aqueous solution with or without BAK across the rabbit sclera was evaluated using a two-chamber Ussing apparatus. To determine the effects of BAK on transscleral delivery of large molecules, 20- and 70-kDa fluorescein isothiocyanate (FITC)-dextran (FD-20 and -70, respectively) aqueous solutions, with or without BAK, were continuously administered to the sclera by an osmotic pump. The intensity of fluorescence in the aqueous humor, vitreous, and retina-choroid was measured by fluorescence spectrophotometry at 1 week after implantation of the pump. The retinal toxicity of BAK was evaluated electrophysiologically and histologically.
RESULTS: BAK increased concentrations of BP in the vitreous and retina-choroid compared with the control. BP was not detected in the aqueous humor. In the in vitro study, BAK did not increase the scleral permeability of BP. In the retina-choroid, BAK significantly increased concentrations of FD-20 but did not increase those of FD-70. The addition of BAK did not increase concentrations of FD-20 or -70 in the vitreous. No substantial toxic reactions were observed in the retina in electrophysiological or histologic examinations after the addition of BAK.
CONCLUSIONS: The results of this study demonstrate that BAK may improve the ocular penetration of a drug in a transscleral drug delivery system without producing toxic reactions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15671302     DOI: 10.1167/iovs.03-0934

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  14 in total

1.  Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics.

Authors:  Ketan Hippalgaonkar; Ramesh Srirangam; Bharathi Avula; Ikhlas A Khan; Soumyajit Majumdar
Journal:  Drug Metab Dispos       Date:  2010-07-01       Impact factor: 3.922

2.  Trans-conjunctival aqueous humor outflow in glaucomatous patients treated with prostaglandin analogues: an in vivo confocal microscopy study.

Authors:  Rodolfo Mastropasqua; Vincenzo Fasanella; Emilio Pedrotti; Manuela Lanzini; Silvio Di Staso; Leonardo Mastropasqua; Luca Agnifili
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-28       Impact factor: 3.117

3.  Effect of menthol on ocular drug delivery.

Authors:  Xiaolin Xu; Nannan Yu; Zhengzhong Bai; Yanbin Xun; Di Jin; Zhijian Li; Hao Cui
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-05-20       Impact factor: 3.117

4.  Modeling of corneal and retinal pharmacokinetics after periocular drug administration.

Authors:  Aniruddha C Amrite; Henry F Edelhauser; Uday B Kompella
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-01       Impact factor: 4.799

5.  Monitoring of glucose permeability in monkey skin in vivo using Optical Coherence Tomography.

Authors:  Mohamad G Ghosn; Narendran Sudheendran; Mark Wendt; Adrian Glasser; Valery V Tuchin; Kirill V Larin
Journal:  J Biophotonics       Date:  2010-01       Impact factor: 3.207

Review 6.  Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.

Authors:  Gábor Holló; Andreas Katsanos; Kostas G Boboridis; Murat Irkec; Anastasios G P Konstas
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

7.  Evaluation of the intravenous and topical routes for ocular delivery of hesperidin and hesperetin.

Authors:  Ramesh Srirangam; Ketan Hippalgaonkar; Bharathi Avula; Ikhlas A Khan; Soumyajit Majumdar
Journal:  J Ocul Pharmacol Ther       Date:  2012-07-13       Impact factor: 2.671

Review 8.  The ocular surface epithelial barrier and other mechanisms of mucosal protection: from allergy to infectious diseases.

Authors:  Flavio Mantelli; Jerome Mauris; Pablo Argüeso
Journal:  Curr Opin Allergy Clin Immunol       Date:  2013-10

9.  Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial.

Authors:  Dai Woo Kim; Jonghoon Shin; Chang Kyu Lee; Myungjin Kim; Sohyeon Lee; Seungsoo Rho
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

10.  A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits.

Authors:  Françoise Brignole-Baudouin; Nicolas Desbenoit; Gregory Hamm; Hong Liang; Jean-Pierre Both; Alain Brunelle; Isabelle Fournier; Vincent Guerineau; Raphael Legouffe; Jonathan Stauber; David Touboul; Maxence Wisztorski; Michel Salzet; Olivier Laprevote; Christophe Baudouin
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.